Eli Lilly and Company (NYSE:LLY) stock is expected to deviate a maximum of $15.96 from the average target price of $94.58 for the short term period. 12 Street Experts have initiated coverage on the stock with the most promising target being $116 and the most muted being $55.
Other Equity analysts have also commented on the company shares. In the latest statement by the brokerage house, Leerink Swann maintains its outlook on Eli Lilly and Company (NYSE:LLY). The current rating of the shares is Outperform, according to the research report released by the firm. The brokerage firm raises the price target from $96 per share to $101 per share. The rating by the firm was issued on May 2, 2016.
Eli Lilly and Company (NYSE:LLY): stock turned positive on Thursday. Though the stock opened at $73.59, the bulls momentum made the stock top out at $73.94 level for the day. The stock recorded a low of $73.2 and closed the trading day at $73.94, in the green by 1.19%. The total traded volume for the day was 2,989,745. The stock had closed at $73.07 in the previous days trading.
The company shares have dropped -13.83% from its 1 Year high price. On Sep 17, 2015, the shares registered one year high at $92.85 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $74.92 and the 200 Day Moving Average price is recorded at $76.77. On the companys insider trading activities, Barnes Melissa S, officer (Chief Eth/Cmpl Ofcr & SVP, ERM) of Lilly Eli & Co, unloaded 992 shares at an average price of $73.77 on June 10, 2016. The total amount of the transaction was worth $73,180, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.